CADX - Cadence Pharmaceuticals Inc

/nm

Been watching this one for a few days, too.. looks like it just broke $6.. we'll see tomorrow.

edit: i'm a dumb newb. ignore me :P

Grave-digging FDA Plays!!!

FDA Calendar Updates: CADX, JNJ, TRGT, WPI
Posted by: Mike Havrilla in Untagged on Jul 15, 2009

On 7/15/09, Cadence Pharma (NASDAQ:CADX) announced that its New Drug Application (NDA) for Acetavance (intravenous acetaminophen), its investigational product candidate for the treatment of acute pain and fever in adults and children, has been accepted for filing by the FDA and designated for a priority (six-month) review. The FDA has issued a PDUFA action date for the NDA of 11/13/09 for a possible decision by the Agency. The Company's 505(b)(2) NDA for Acetavance includes data from one pivotal clinical trial for the treatment of acute pain in patients following orthopedic surgery and one pivotal clinical trial for the treatment of endotoxin-induced fever.

The NDA is also supported by data from a total of nine placebo-controlled clinical trials, four active-controlled clinical trials, and seven other safety or pharmacokinetic clinical trials. The submission includes safety data from over 1,400 patients who received Acetavance in clinical trials, including 350 pediatric patients, from premature neonates to adolescents, and data from safety reports that collectively represent more than 53 million patient exposures to intravenous acetaminophen in countries outside of the U.S.

http://biomedreports.com/blog/FDA-Ca...-TRGT-WPI.html

alright, who is playing the FDA decision tomorrow... any... GAMBLERS?

(not I)

http://www.biohealthinvestor.com/200...dufa-cadx.html

g

New PDUFA date 11/4/2010; I like this anywhere under $9 unless the huge support at $8.50 (which goes to back to March '09 and isn't displayed on this chart) breaks down...

Cadence Pharmaceuticals Signs Option Agreement to Acquire Incline TherapeuticsLast update: 6/21/2010 4:00:00 PMCompany Also Closes $30 Million Debt Financing SAN DIEGO, June 21, 2010 /PRNewswire via COMTEX/ -- Cadence Pharmaceuticals, Inc. (CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that it has signed an agreement providing Cadence with an exclusive option to acquire Incline Therapeutics, Inc., a privately held specialty pharmaceutical company. The company simultaneously announced that it has closed a $30 million secured loan facility with Oxford Finance Corporation, Silicon Valley Bank and GE Financial Services, Inc.

http://bit.ly/ddVLfh

Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever

and no1 is impressed ... says the AH action

It ran up $3 in almost a straight line. Everyone that wanted to get in is in and now they want profits.

^God that 2nd sentence sounds bad

Secondary Public Offering DetailsProvided by MorningNotes®MorningNotes® RatingView Rating Scale C+
Secondary Public Offering Filed On 11/14/11
Registration Period 1 Day(s)
Offer Date 11/15/11

Deal SizeView Deal Breakdown 14,822,134
Price Range --
Deal Value $75.0M
Trade Date 11/15/11
Settlement Date 11/18/11
Priced 19.0M Shares @ $3.75
Revenue $10.8M
Net Income -$65.4M
Deal Underwriters
Deutsche Bank Securities; Leerink Swann
K: Thousands, M: Millions, B: Billions

going the wrong way for a while now

down 40% the 6 months before secondary off...now down another 50% in the 6 months since